Latest Update — As of September 1, 2026: The Depo-Provera litigation has moved past the pretrial stage described above. On June 15, 2026, Pfizer and plaintiffs’ leadership announced a global settlement in principle, and on July 21, 2026 they signed a formal Master Settlement Agreement expected to cover roughly 80% of plaintiffs currently in the MDL. The court appointed BrownGreer PLC as settlement administrator on August 5, 2026. Registration is expected to wrap up in November 2026, with claims processing and first payments projected for early 2027. The first bellwether trial, once set for December 2026, has been canceled as a result. Eligibility rules and payout terms have not been made public. A Rule 702/general causation hearing covering claims outside the settlement is now set for September 18, 2026.
Last updated: September 2026
Thousands of women are suing Pfizer over Depo-Provera, a popular contraceptive injection linked to a serious type of brain tumor called meningioma. The depo-provera lawsuit is one of the fastest-growing mass tort cases in the country right now.
By early 2026, the federal litigation has grown to include thousands of individual claims consolidated under a single federal court. Women who used the shot and later developed meningioma are at the center of this fight.
This article covers everything: what the lawsuit claims, who qualifies, what payouts could look like, where the cases stand in court right now, and what you need to do if you think you have a claim.
One fact that surprises most people: a 2023 French government study found that women who used high-dose progestin contraceptives were nearly three times more likely to develop meningioma.
What Is the Depo-Provera Lawsuit?
The Depo-Provera lawsuit is a mass tort legal action claiming Pfizer failed to warn patients about a known link between its contraceptive injection and intracranial meningioma, a type of brain tumor.
The lawsuits are not based on a new theory. Research connecting progestin-based hormones to meningioma growth goes back decades. Pfizer’s critics argue the company had enough data to update warning labels long before it did.
Plaintiffs say they would have made different choices about their contraception if they had been told the real risks. That’s the core of the failure to warn claim that ties these cases together.
The drug itself, marketed as Depo-Provera, is a quarterly injection containing medroxyprogesterone acetate. It’s been prescribed to women in the United States since 1992.
| Basic Case Facts | Details |
|---|---|
| Drug at Issue | Depo-Provera (medroxyprogesterone acetate) |
| Manufacturer Sued | Pfizer Inc. |
| Primary Injury Claimed | Intracranial meningioma (brain tumor) |
| Legal Theory | Failure to warn, product liability |
| Court | U.S. District Court, Northern District of Illinois |
| MDL Number | MDL No. 3140 |
What Is the Depo-Provera Brain Tumor Lawsuit?
The Depo-Provera brain tumor lawsuit specifically targets the alleged connection between long-term use of the injection and the development of meningioma tumors.
Meningiomas grow in the membranes surrounding the brain and spinal cord. Most are benign, but even non-cancerous meningiomas can cause serious problems. Pressure on the brain from tumor growth leads to headaches, vision loss, memory problems, and in severe cases, permanent disability requiring surgery.
Plaintiffs in these cases typically had the tumor discovered after years of using the shot. Many required surgery to remove the tumor. Others face ongoing monitoring and the possibility of regrowth.
The brain tumor angle is what gives this lawsuit its weight. This is not a minor side effect claim. These are life-altering injuries.
Key stat: Studies suggest women who used high-dose progestin contraceptives for more than one year face significantly elevated meningioma risk compared to non-users.
What Is the Depo-Provera Lawsuit Against Pfizer?
The Depo-Provera lawsuit against Pfizer centers on the argument that Pfizer had access to safety data and scientific literature suggesting meningioma risk but chose not to update its warning labels adequately.
Pfizer acquired Depo-Provera when it bought Pharmacia in 2003. Before Pfizer, Upjohn developed the drug and got FDA approval in 1992. The failure to warn claims trace a long corporate timeline of alleged inaction.
Plaintiffs argue that Pfizer’s U.S. prescribing information did not include a meaningful meningioma warning even as European regulators began acting on that data. France’s drug safety agency issued a warning about progestins and meningioma risk as early as 2021.
By the time Pfizer updated its U.S. label in late 2023, thousands of women had already been using the product for years without knowing about the risk.
- Pfizer is the named defendant in the vast majority of filed claims
- Claims also involve Pfizer’s predecessor companies and their handling of safety data
- The failure to warn theory is the primary legal basis across all filings
What Does Medroxyprogesterone Acetate Do in the Brain?
Medroxyprogesterone acetate is a synthetic progestin, meaning it mimics the hormone progesterone in the body. The medroxyprogesterone acetate brain tumor connection comes down to how this compound interacts with hormone receptors in brain tissue.
Meningioma tumors frequently express progesterone receptors. This means they can respond to hormonal signals. When medroxyprogesterone acetate binds to those receptors, researchers believe it may stimulate tumor growth or accelerate the development of tumors that would otherwise remain dormant.
The 2023 study published in the British Medical Journal, drawing on French national health data, found that women who used high-dose progestins like medroxyprogesterone acetate faced a nearly threefold increased risk of developing meningioma. That study involved over 100,000 women.
Think of it like fertilizer for a seed that’s already in the ground. The tumor may have been there in a microscopic, harmless form. The hormonal exposure from Depo-Provera may have given it what it needed to grow into something dangerous.
| Scientific Evidence | Key Finding |
|---|---|
| 2023 BMJ / French cohort study | ~3x increased meningioma risk with high-dose progestin use |
| Sample size | Over 100,000 women observed |
| Risk threshold | Risk appeared elevated with more than 12 months of use |
| Progesterone receptor link | Meningiomas often express progesterone receptors |
What Is the Depo-Provera Meningioma Lawsuit?
The Depo-Provera meningioma lawsuit is the specific subset of claims where plaintiffs were diagnosed with intracranial meningioma after using the contraceptive injection, typically for an extended period.
Meningioma is the single most common primary brain tumor in adults. It accounts for roughly 37 percent of all primary brain tumors diagnosed in the United States. Women are diagnosed at roughly twice the rate of men, a disparity researchers have long suspected has a hormonal explanation.
Not every meningioma case qualifies. The lawsuits focus on women who used Depo-Provera for a sustained period, generally more than one year, and who subsequently received a confirmed meningioma diagnosis. The timing and duration of use matter significantly.
- Plaintiffs must have a documented Depo-Provera prescription history
- A confirmed meningioma diagnosis, typically by MRI or surgical pathology, is required
- Claims must establish a plausible timeline between use and diagnosis
Key Takeaway: The three core elements of a qualifying claim are confirmed Depo-Provera use, a meningioma diagnosis, and a timeline that connects the two.
What Are the Depo-Provera Side Effects at the Center of the Lawsuit?
The Depo-Provera side effects lawsuit focuses primarily on meningioma, but the broader litigation touches on a range of serious conditions plaintiffs say were inadequately disclosed.
The FDA-approved label for Depo-Provera did include warnings about bone density loss and certain other risks. What it conspicuously did not include, plaintiffs argue, was a clear, prominent warning about meningioma risk, particularly for long-term users.
Some plaintiffs in the broader litigation allege other serious hormonal effects, including cardiovascular complications and delayed return to fertility. But the brain tumor claims dominate the legal landscape right now because they represent the most severe documented injury.
The practical reality: if you took Depo-Provera and experienced something serious beyond what your doctor told you to expect, your situation may be worth evaluating by a plaintiff’s attorney.
- Primary side effect at issue: intracranial meningioma
- Secondary claims: bone density loss, cardiovascular effects, delayed fertility
- Central legal argument: Pfizer knew or should have known about meningioma risk and failed to communicate it
Who Qualifies for the Depo-Provera Lawsuit?
Women who used Depo-Provera injections and were later diagnosed with meningioma are the primary group who may qualify for the depo-provera lawsuit.
Qualification is not automatic. Cases are individually evaluated based on the strength of the medical record and the timeline of drug use. An attorney experienced in pharmaceutical mass torts would review your records before deciding whether to take your case.
That said, there are general patterns that appear in most qualifying claims. Look at this breakdown:
| Qualifying Factor | General Requirement |
|---|---|
| Drug used | Depo-Provera (brand or generic medroxyprogesterone acetate) |
| Duration of use | Generally 12 or more months |
| Diagnosis required | Intracranial meningioma confirmed by MRI or pathology |
| Prescription records | Medical records showing documented use |
| Timing | Diagnosis occurring during or after period of use |
| Exclusions | Other known meningioma causes may complicate claims |
Women who used Depo-Provera briefly, such as one or two injections, may face a harder path. The research most strongly supports claims involving sustained, long-term use.
What Are the Depo-Provera Lawsuit Eligibility Requirements?
The Depo-Provera lawsuit eligibility requirements go beyond simply having used the drug and received a diagnosis.
Attorneys and courts look at several factors when evaluating whether a case is viable. The strongest claims include documented prescription records, a clear meningioma diagnosis with imaging or surgical confirmation, and a timeline showing use predated the tumor diagnosis.
Women who had other hormonal conditions, prior meningioma history, or other potential contributing causes may still have claims. But those cases require more detailed medical review.
Here’s what helps establish a strong claim:
- Medical records showing Depo-Provera prescriptions and injection dates
- Radiology reports, MRI scans, or surgical pathology confirming meningioma
- A diagnosis timeline consistent with the research (tumor identified during or after use)
- No prior history of meningioma before starting the injections
- Documentation of symptoms such as headaches, vision changes, or cognitive issues
Key Takeaway: The most important documents you can gather right now are your prescription history, injection records, and any brain imaging reports you received after your diagnosis.
Is the Depo-Provera Class Action Lawsuit a Class Action or Something Else?
The Depo-Provera class action lawsuit terminology gets used loosely online, but technically this litigation is structured as a Multi-District Litigation, not a traditional class action.
That distinction matters. In a class action, all plaintiffs share one settlement and receive similar amounts. In an MDL, each plaintiff maintains their own individual case. Cases are consolidated before one judge for pretrial proceedings to save time and resources, but each claimant’s facts and injuries are evaluated separately.
This structure actually benefits plaintiffs with serious injuries. Someone who needed brain surgery and spent months in recovery will not receive the same amount as someone with a smaller, untreated tumor. The individual case structure means compensation reflects actual harm.
| Feature | Class Action | MDL (This Litigation) |
|---|---|---|
| Case structure | All plaintiffs share one case | Individual cases consolidated |
| Payout uniformity | Similar amounts for all | Based on individual damages |
| Settlement process | One global settlement | Individual or global resolution |
| Who controls your case | Lead attorneys | Your own attorney |
| Best for | Minor, uniform harms | Serious, variable injuries |
What Is the Depo-Provera MDL Lawsuit?
The Depo-Provera MDL lawsuit is formally known as MDL No. 3140, established in the U.S. District Court for the Northern District of Illinois in early 2024.
MDL stands for Multi-District Litigation. When thousands of similar federal lawsuits are filed across the country, a judicial panel consolidates them before one judge. That judge handles all pretrial matters: discovery, motions, expert witnesses, and the selection of bellwether cases.
By late 2024, hundreds of cases had been filed and transferred to the MDL. By 2026, estimates put the total filed claims in the thousands. The MDL judge will select a small number of bellwether cases to go to trial first. Those verdicts signal to both sides what juries think of the evidence, which usually leads to broader settlement talks.
The MDL judge presiding over this litigation is a critical figure. Bellwether trial outcomes in 2026 will likely shape the settlement value for every other claimant in the pool.
- MDL No. 3140 is the official case designation
- Filed in the Northern District of Illinois
- Bellwether trials are expected to begin in 2026
- MDL status does not mean your case is resolved, it means pretrial coordination is centralized
What Are the Latest Updates in the Depo-Provera Lawsuit 2026?
The Depo-Provera lawsuit 2026 status reflects a litigation that has moved through initial MDL formation and is now approaching the most critical phase: bellwether trials.
As of early 2026, the MDL is in active pretrial litigation. Discovery is ongoing, meaning both sides are exchanging documents, deposing experts, and building their scientific cases. Pfizer has challenged the plaintiffs’ expert testimony on causation, a standard defense tactic in pharmaceutical mass torts.
The bellwether cases selected for early trials will test how juries respond to the meningioma evidence. If plaintiffs win those early trials with large verdicts, Pfizer faces enormous pressure to settle the broader docket. If defense wins, settlement values drop.
The 2026 bellwether trial outcomes are arguably the most important events in this entire litigation. Watch them closely.
| 2026 Litigation Milestones | Expected Timing |
|---|---|
| Pretrial discovery | Ongoing through mid-2026 |
| Expert witness challenges (Daubert) | Early to mid-2026 |
| Bellwether trial selection finalized | Mid-2026 |
| First bellwether trials | Late 2026 |
| Broader settlement discussions | Late 2026 or into 2027 |
Key Takeaway: The Depo-Provera litigation enters its most decisive phase in 2026, with bellwether trials expected to shape whether and how Pfizer settles the broader pool of claims.
What Are the Latest Depo-Provera Lawsuit Updates?
The depo-provera lawsuit update picture through early 2026 shows an aggressive MDL with significant plaintiff momentum, but also a well-funded defense from Pfizer.
Pfizer updated the U.S. prescribing information for Depo-Provera in late 2023 to include meningioma language. Plaintiff attorneys argue that update actually strengthens their cases. It confirms Pfizer knew the risk was real. The question becomes: why did it take so long?
On the plaintiff side, new studies continue to emerge supporting the biological mechanism linking medroxyprogesterone acetate to meningioma growth. That growing scientific record makes it harder for Pfizer to argue the risk was unknowable.
Courts are also seeing new plaintiffs join the MDL regularly. The docket continues to grow as more women learn about the litigation and connect their diagnoses to their contraceptive history.
- Pfizer updated its label in late 2023, acknowledging meningioma risk
- New scientific research continues to support plaintiff causation arguments
- MDL docket growing steadily through early 2026
- Defense is challenging expert testimony, a normal but important pretrial battle
What Is the Depo-Provera Lawsuit Settlement Amount?
No global settlement in the Depo-Provera lawsuit has been reached as of early 2026, so there are no confirmed settlement amounts to report. But the range of potential compensation can be estimated based on comparable pharmaceutical mass torts.
Settlement values in cases like this depend on what lawyers call “damages tiers.” Someone who had a meningioma that required immediate surgery, followed by a long recovery, will receive far more than someone whose tumor was small and surgically removed without complications.
Here is a realistic look at how settlement tiers tend to work in cases of this nature:
| Injury Tier | Description | Estimated Compensation Range |
|---|---|---|
| Tier 1 (Most Severe) | Surgery, major neurological damage, disability | $500,000 to several million |
| Tier 2 (Moderate) | Surgery required, partial recovery, ongoing monitoring | $150,000 to $500,000 |
| Tier 3 (Less Severe) | Meningioma confirmed, managed without major surgery | $50,000 to $150,000 |
| Tier 4 (Monitoring Only) | Diagnosed, watchful waiting, no surgery yet | To be determined in negotiation |
These are not guaranteed figures. They reflect patterns from comparable pharmaceutical settlements and are subject to change based on trial outcomes.
How Much Is the Depo-Provera Lawsuit Worth?
How much the Depo-Provera lawsuit is worth overall depends on how many claimants have valid cases and what the bellwether trials reveal about jury behavior.
Industry analysts who follow pharmaceutical mass torts have estimated the total litigation could represent billions of dollars in potential liability for Pfizer if the science holds up in court. Pfizer is a company with annual revenues exceeding $50 billion, so settlement capacity is not the constraint here. The question is what value the evidence supports.
Individual claim value breaks down like this:
- Severity of diagnosis: Was the meningioma large? Did it cause neurological damage?
- Surgical history: Did you need a craniotomy or other surgery?
- Recovery: How long were you out of work? What ongoing effects remain?
- Duration of Depo-Provera use: Longer use typically strengthens causation arguments
- Medical costs: Past and future medical expenses factor into economic damages
- Pain and suffering: Non-economic damages that vary widely by jurisdiction
The strongest individual claims, those involving surgery, disability, and prolonged suffering, could be worth seven figures. Claims involving smaller tumors with minimal impact are likely worth significantly less.
What Is the Depo-Provera Lawsuit Filing Deadline?
The Depo-Provera lawsuit filing deadline is not a single universal date. Each state has its own statute of limitations for personal injury claims, and those deadlines vary.
Most states allow between two and three years from the date of injury or the date you discovered the connection between your injury and the drug. The “discovery rule” is critical here. If you only recently learned that your meningioma may be connected to Depo-Provera use, your clock may not have started yet.
| State Statute of Limitations | General Timeframe |
|---|---|
| California | 2 years from discovery |
| Texas | 2 years from injury or discovery |
| New York | 3 years from injury |
| Florida | 2 years from discovery (recent change) |
| Illinois | 2 years from injury or discovery |
The single most important thing to understand about deadlines: waiting to file is the one thing that can eliminate your legal options entirely, even if you have a strong claim.
Courts do not grant extensions simply because you didn’t know the deadline existed. The time to act is now, in 2026, before state-specific windows close.
Key Takeaway: Filing deadlines vary by state and are tied to either the injury date or the discovery of the drug connection. Missing your state’s deadline means losing your right to compensation permanently.
How Do You Join the Depo-Provera Lawsuit?
Joining the Depo-Provera lawsuit involves contacting a plaintiff’s attorney who handles pharmaceutical mass tort cases, not filing paperwork on a government website.
This is not a class action where you submit a simple claim form online. Because this is an MDL with individual cases, you need an attorney to evaluate your specific facts, gather your medical records, and file a formal complaint on your behalf in federal court.
Here is how the process typically works:
- Step 1: Contact a mass tort attorney for a free case evaluation
- Step 2: Provide basic information about your Depo-Provera use history and your diagnosis
- Step 3: The attorney reviews your medical records and determines if your case qualifies
- Step 4: If you have a viable claim, the attorney files a complaint in federal court
- Step 5: Your case is transferred to MDL No. 3140 for pretrial coordination
- Step 6: You participate in discovery, potentially including your own deposition
- Step 7: Your case either settles individually or goes to trial as a bellwether or later case
Most plaintiff’s attorneys in mass tort cases work on a contingency fee basis. That means you pay nothing upfront and the attorney takes a percentage of your recovery only if you win.
The process takes time. Don’t expect a check in 2026 unless you are among the earliest bellwether cases. But the earlier you file, the better your position.
Frequently Asked Questions
What is the Depo-Provera lawsuit about?
The Depo-Provera lawsuit claims that Pfizer failed to warn patients that the contraceptive injection causes intracranial meningioma, a type of brain tumor.
Women who developed meningioma after extended Depo-Provera use are suing for medical costs, pain and suffering, and other damages.
The litigation is centralized as MDL No. 3140 in the Northern District of Illinois.
Who qualifies for the Depo-Provera lawsuit in 2026?
Women who used Depo-Provera injections for an extended period, generally 12 or more months, and who were later diagnosed with meningioma are the primary qualifying group.
You will need documented prescription records and a confirmed meningioma diagnosis from imaging or surgery.
Cases are evaluated individually, so speaking with a mass tort attorney is the only way to know for certain if your situation qualifies.
How much money could I get from a Depo-Provera settlement?
No global settlement has been reached as of early 2026, so exact amounts are not confirmed.
Based on comparable pharmaceutical mass torts, estimates range from tens of thousands for minor diagnoses to over one million dollars for cases involving surgery and permanent neurological damage.
Bellwether trial results in 2026 will heavily influence final settlement values across the MDL.
Is the Depo-Provera lawsuit a class action or an MDL?
The Depo-Provera litigation is structured as a Multi-District Litigation, or MDL, not a traditional class action.
Each plaintiff keeps their own individual case; the MDL just consolidates pretrial proceedings before one federal judge.
This structure means your compensation will reflect your specific injuries rather than a flat amount shared equally with thousands of others.
What is the deadline to file a Depo-Provera lawsuit claim?
There is no single universal deadline. Each state has its own statute of limitations, typically two to three years from the date of injury or the date you discovered the connection to Depo-Provera.
The discovery rule often extends the deadline for people who only recently connected their diagnosis to their contraceptive history.
Waiting is the biggest risk. Contact an attorney in 2026 to confirm your specific state’s deadline before time runs out.
Where Things Stand and What to Do Now
The Depo-Provera litigation is real, it’s growing, and 2026 is when the most important developments happen. Bellwether trials will set the tone. Scientific evidence continues to support the plaintiffs. Pfizer’s own label update confirms the company now acknowledges the risk.
If you used Depo-Provera and received a meningioma diagnosis, gather your medical records now. Your prescription history, injection dates, and brain imaging reports are the foundation of any claim.
Reach out to a mass tort attorney for a free evaluation. Time limits are real and they are not forgiving.
